Fulcrum Therapeutics (NASDAQ:FULC) Shares Up 3% – Should You Buy?

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) shares rose 3% during trading on Monday . The stock traded as high as $11.90 and last traded at $11.93. Approximately 195,038 shares were traded during mid-day trading, a decline of 74% from the average daily volume of 750,368 shares. The stock had previously closed at $11.58.

Analyst Ratings Changes

A number of equities analysts have issued reports on FULC shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Wednesday, October 8th. HC Wainwright increased their price objective on Fulcrum Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Wall Street Zen raised Fulcrum Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. Piper Sandler reaffirmed an “overweight” rating and set a $23.00 price target (up previously from $16.00) on shares of Fulcrum Therapeutics in a research report on Monday, December 8th. Finally, Leerink Partners set a $20.00 price objective on shares of Fulcrum Therapeutics and gave the company an “outperform” rating in a report on Tuesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $19.00.

Fulcrum Therapeutics Stock Performance

The stock has a market cap of $642.95 million, a price-to-earnings ratio of -10.07 and a beta of 3.17. The company has a 50-day simple moving average of $10.39 and a two-hundred day simple moving average of $8.49.

Fulcrum Therapeutics (NASDAQ:FULC) last released its earnings results on Wednesday, October 29th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.02). As a group, sell-side analysts predict that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current fiscal year.

Insider Transactions at Fulcrum Therapeutics

In other news, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $13.98, for a total value of $58,368,443.22. Following the completion of the sale, the insider directly owned 6,053,960 shares of the company’s stock, valued at $84,634,360.80. This trade represents a 40.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Robert J. Gould sold 15,000 shares of Fulcrum Therapeutics stock in a transaction that occurred on Wednesday, November 19th. The stock was sold at an average price of $11.03, for a total value of $165,450.00. Following the transaction, the director owned 484,864 shares of the company’s stock, valued at $5,348,049.92. This represents a 3.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 7.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Fulcrum Therapeutics

Several hedge funds have recently added to or reduced their stakes in FULC. Acadian Asset Management LLC boosted its stake in Fulcrum Therapeutics by 865.0% in the 1st quarter. Acadian Asset Management LLC now owns 344,561 shares of the company’s stock valued at $989,000 after purchasing an additional 308,854 shares during the period. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Fulcrum Therapeutics during the first quarter worth $425,000. Exome Asset Management LLC boosted its position in shares of Fulcrum Therapeutics by 143.0% in the first quarter. Exome Asset Management LLC now owns 689,137 shares of the company’s stock valued at $1,985,000 after acquiring an additional 405,538 shares during the period. Strs Ohio acquired a new position in shares of Fulcrum Therapeutics in the first quarter valued at about $263,000. Finally, Bailard Inc. bought a new position in Fulcrum Therapeutics during the second quarter worth about $185,000. Institutional investors and hedge funds own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.